US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
biotech · Major Depressive Disorder · Schizophrenia · NBIX
NEUROCRINE BIOSCIENCES
NEUROCRINE BIOSCIENCES INC
NEUROCRINE BIOSCIENCES drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
6027 Edgewood Bend Ct, San Diego, California 92130, US HQ
1992 Founded
2,307 Employees
Public company Type
NBIX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 6027 Edgewood Bend Ct, San Diego, California 92130, US
- Founded
- 1992
- Employees
- 2,307
- Programs
- 5
- Drugs
- 16
- Patents
- 27
NEUROCRINE BIOSCIENCES pipeline
Portfolio lens on 16 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
NEUROCRINE BIOSCIENCES drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to NEUROCRINE BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Corticotropin-releasing factor receptor 1.
- Target
- Corticotropin-releasing factor receptor 1
- Mechanism
- Corticotropin releasing factor receptor 1 antagonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to NEUROCRINE BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
enoxaparin sodium
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
hydrocortisone
Systemic hormonal preparations (H02)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
ketoconazole
Antiinfectives for systemic use (J02)US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
Development asset linked to NEUROCRINE BIOSCIENCES in public FDA and regional records.
-
opicapone
Nervous system (N04)US regulatory status: approved. Molecular target: Catechol O-methyltransferase.
- Target
- Catechol O-methyltransferase
- Mechanism
- Catechol O-methyltransferase inhibitor
-
Development asset linked to NEUROCRINE BIOSCIENCES in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Synaptic vesicular amine transporter.
- Target
- Synaptic vesicular amine transporter
- Mechanism
- Synaptic vesicular amine transporter inhibitor
-
US regulatory status: approved. Molecular target: Synaptic vesicular amine transporter.
- Target
- Synaptic vesicular amine transporter
- Mechanism
- Synaptic vesicular amine transporter inhibitor